About Longeveron Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.longeveron.com/
Frequently Asked Questions
What is the 52-week range for LGVN?
The 52-week high is $12.3 and the 52-week low is $2.3001.
What is the P/E ratio for LGVN?
The P/E ratio data is currently unavailable.
What is the dividend yield for LGVN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -223.19%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1977.59%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.90.
Analyst Recommendation Trends
Wall Street analyst consensus for LGVN over the last few months:
Latest LGVN News
Longeveron to Participate in Three Longevity/Aging Investment Conferences
New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxivMIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longe
Longeveron ELPIS II Trial Did Not Meet Primary Efficacy Endpoint
-SEC Filing
Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?
Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study evaluated laromestrocel as an adjunct to Stage 2 palliative heart surgery. The primary endpoint measured change in right ventricular ejection fraction, an indicator of pumping […]
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular session. The market value of their outstanding shares is at $1.0 million. SkyAI (NASDAQ:SKYA) stock rose 20.43% to
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
Top movers in Thursday's session
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Here are the top movers in Thursday's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Let's uncover which stocks are experiencing notable gaps during today's session.
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies (NASDAQ:BIAF) shares
These stocks are moving in today's pre-market session
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
LGVN Posts Disappointing Trial Results
By Brad Sorensen, CFA NASDAQ: LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron’s (NASDAQ: LGVN) September 16 announcement represents an important turning point for the company. The Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome, or HLHS, failed to meet its primary efficacy endpoint, a result that understandably caused a sharp reset in investor expectations. The
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $1.0 million. Akanda (NASDAQ:AKAN) stock rose 15.07% to $3.13.
Why Generac Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Generac shares jumped 34.8% after an up-to-$8B Amazon data-center generator deal; other premarket movers included big gainers and losers.
Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why
Longeveron shares fell 59% after hours after its ELPIS II trial missed its primary endpoint.
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHSLaromestrocel has
Longeveron Announces Phase 2b ELPIS II Trial Of Laromestrocel In Hypoplastic Left Heart Syndrome Misses Primary Efficacy Endpoint; Initiates Cost-Optimization Measures To Maximize Shareholder Value
The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-19 | Lehr Paul T | +286,000 | - | - |
| 2026-08-19 | Hajjar Roger Joseph | +36,000 | - | - |
| 2026-08-19 | Soffer Rock | +36,000 | - | - |
| 2026-08-19 | Paletta George A. Jr. | +36,000 | - | - |
| 2026-08-19 | Ungaro Ursula | +36,000 | - | - |
| 2026-08-19 | Desai Arjun JJ | +36,000 | - | - |
| 2026-08-19 | Blass Devin | +286,000 | - | - |
| 2026-08-19 | Agafonova Nataliya | +286,000 | - | - |
| 2026-08-19 | Ascheim Deborah | +36,000 | - | - |
| 2026-08-19 | Cann Leah Rush | +36,000 | - | - |
| 2026-08-19 | Hare Joshua | +286,000 | - | - |
| 2026-08-17 | Jhaveri Nirav S. | +300,000 | - | - |
| 2026-07-06 | Hare Joshua | +400,000 | - | - |
| 2026-07-06 | Hare Joshua | +600,000 | - | - |
| 2026-07-01 | Locklear Lisa | -22,505 | $0.7291 | $16,408 |
| 2026-07-01 | Agafonova Nataliya | -22,505 | $0.7291 | $16,408 |
| 2026-07-01 | Blass Devin | -15,808 | $0.7291 | $11,526 |
| 2026-07-01 | Lehr Paul T | -13,143 | $0.7291 | $9,583 |
| 2026-07-01 | Willard Stephen H | -18,046 | $0.7291 | $13,157 |
| 2026-05-01 | Lehr Paul T | +250,000 | - | - |
| 2026-05-01 | Blass Devin | +250,000 | - | - |
| 2026-05-01 | Agafonova Nataliya | +250,000 | - | - |
| 2026-05-01 | Locklear Lisa | +250,000 | - | - |
| 2026-05-01 | Willard Stephen H | +500,000 | - | - |
| 2026-04-01 | Lehr Paul T | -5,611 | $1.12 | $6,284 |
| 2026-04-01 | Agafonova Nataliya | -13,145 | $1.12 | $14,722 |
| 2026-04-01 | Locklear Lisa | -13,145 | $1.12 | $14,722 |
| 2026-04-01 | Blass Devin | -8,633 | $1.12 | $9,669 |
| 2026-04-01 | Willard Stephen H | -4,740 | $1.12 | $5,309 |
| 2026-03-02 | Willard Stephen H | +200,000 | - | - |
| 2026-03-02 | Willard Stephen H | +200,000 | - | - |
| 2026-03-02 | Willard Stephen H | -105,533 | $0.545 | $57,515 |
| 2026-03-02 | Willard Stephen H | +200,000 | - | - |
| 2026-01-02 | Agafonova Nataliya | -10,250 | $0.593 | $6,078 |
| 2026-01-02 | Lehr Paul T | -6,952 | $0.593 | $4,123 |
| 2026-01-02 | Locklear Lisa | -10,250 | $0.593 | $6,078 |
| 2026-01-02 | Blass Devin | -10,700 | $0.593 | $6,345 |
| 2026-01-02 | Powell James Nathaniel | -2,464 | $0.593 | $1,461 |